Article Text

Download PDFPDF
High effectiveness of short treatment with bupropion for smoking cessation in general care
  1. L P Breitling,
  2. D Twardella,
  3. H Brenner
  1. 1
    Division of Clinical Epidemiology and Aging Research, German Cancer Research Centre, Heidelberg, Germany
  1. Dr L P Breitling, Division of Clinical Epidemiology and Aging Research, German Cancer Research Centre, Bergheimer Str 20, D-69115 Heidelberg, Germany; L.Breitling{at}DKFZ-Heidelberg.de

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Since the appearance of the seminal publication on sustained release bupropion versus placebo for smoking cessation exactly 10 years ago,1 bupropion has become a mainstay of nicotine addiction therapy.2 Some concerns relating to increased risk of seizures remain, in particular as exclusion of predisposed patients may be suboptimal in general practice.3 Furthermore, the cost of about €135 or US$180 for a pack of 100 pills required for a standard course of treatment of at least 7 weeks represents a substantial barrier to wider use.4 We present data suggesting that much shorter treatments with bupropion may be as effective as standard regimens.

In a cluster randomised trial in …

View Full Text

Footnotes

  • Funding: The study was funded by the German Ministry of Education and Research within the Baden–Württemberg Research Network on Addiction, project No 01EB0113. The funding source was not involved in study design, collection, analysis or interpretation of the data, in writing of the report or in the decision to submit for publication. LPB is supported by a grant within the German Research Foundation Priority Programme “Nicotine” (SFB 1226).

  • Competing interests: None.

Linked Articles

  • Letters
    R Beasley